The journey to LDL-C goal in the era of combination lipid lowering therapy and why it matters for ASCVD patients: a UK perspective
This study identifies a therapeutic gap when following a stepwise approach highlighted by recent national guidance. Our proposal of a novel pathway highlights that the order in which drugs are added is important in the context of national reimbursement thresholds and allows LDL-C goal to be reached in a timely manner, regardless of the starting baseline LDL-C level.
Authors
- Ashley M. Miller (ORCID: https://orcid.org/0000-0002-5604-2387)
- Adie Viljoen (ORCID: https://orcid.org/0000-0002-3125-7998)
- Arunesh Sil
- Mohamed Elnaggar (ORCID: https://orcid.org/0000-0003-4415-2789)
Institutions
- University Hospitals of Morecambe Bay NHS Foundation Trust (GB)
- Lister Hospital (GB)
- Sanofi (United Kingdom) (GB)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1080/03007995.2024.2400273
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.57